Clinical management of patients with non-small cell lung cancer, brain metastases, and actionable genomic alterations: a systematic literature review
M Khasraw, P Yalamanchili, A Santhanagopal… - Advances in …, 2024 - Springer
Introduction Nearly 60% of patients with non-small cell lung cancer (NSCLC) present with
metastatic disease, and approximately 20% have brain metastases (BrMs) at diagnosis …
metastatic disease, and approximately 20% have brain metastases (BrMs) at diagnosis …
Epidermal growth factor receptor compound and concomitant mutations: advances in precision treatment strategies
W Li, R Bai, H Guo, J Cui - Chinese Medical Journal, 2023 - mednexus.org
Epidermal growth factor receptor (EGFR) mutations are common oncogenic driver mutations
in patients with non-small cell lung cancer (NSCLC). The application of EGFR-tyrosine …
in patients with non-small cell lung cancer (NSCLC). The application of EGFR-tyrosine …
Epidemiology and Outcomes of Non–Small Cell Lung Cancer in South Korea
HA Jung, DH Lee, SM Lim, H Yu, S Yoon… - JAMA Network …, 2024 - jamanetwork.com
Importance Valuable evidence regarding clinical characteristics, treatments, and outcomes
for non–small cell lung cancer (NSCLC) is limited to individual hospital databases or …
for non–small cell lung cancer (NSCLC) is limited to individual hospital databases or …
[HTML][HTML] The role of brain radiotherapy before first-line afatinib therapy, compared to gefitinib or erlotinib, in patients with EGFR-mutant non-small cell lung cancer
HA Jung, S Park, SH Lee, JS Ahn… - Cancer research and …, 2022 - synapse.koreamed.org
Purpose Brain metastasis is common in patients with epidermal growth factor receptor
(EGFR)–mutant non–small cell lung cancer (NSCLC) at initial presentation. A previous study …
(EGFR)–mutant non–small cell lung cancer (NSCLC) at initial presentation. A previous study …
Real-World Treatment Outcomes and Safety of Afatinib in Advanced Squamous Cell Lung Cancer Progressed after Platinum-Based Doublet Chemotherapy and …
W Ji, IJ Oh, CK Park, SY Lee, J Choi, JC Lee, J Kim… - Cancers, 2023 - mdpi.com
Simple Summary Although the LUX-Lung 8 trial has demonstrated the clinical benefit of
afatinib as a second-line treatment for squamous cell carcinoma of the lung (LSCC), data on …
afatinib as a second-line treatment for squamous cell carcinoma of the lung (LSCC), data on …
A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam
CP Pham, TTH Nguyen, AT Do, TK Nguyen… - BMC cancer, 2024 - Springer
Background This study aimed to evaluate the efficacy and side effects of first-line afatinib
treatment in a real-world setting in Vietnam. Methods This retrospective study was …
treatment in a real-world setting in Vietnam. Methods This retrospective study was …
[HTML][HTML] Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice?
Background Afatinib can be started at a dose lower than the recommended starting dose of
40 mg/day for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small …
40 mg/day for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small …
[HTML][HTML] Real-world first-line afatinib for advanced EGFR mutation-positive non-small cell lung cancer in Korea: updated survival data
J Choi, CM Choi, YS Chang, KY Lee… - Translational Lung …, 2023 - ncbi.nlm.nih.gov
Background Data from clinical trials and real-world studies show that afatinib is effective in
treating non-small cell lung cancer (NSCLC) harboring activating mutations in the epidermal …
treating non-small cell lung cancer (NSCLC) harboring activating mutations in the epidermal …
EP12. 01-67 A Real World Cohort Study of First Line Afatinib in Patients with EGFR mutant Advanced Non Small Cell Lung Cancer in Vietnam
PC Pham, HTT Nguyen, TA Do - Journal of Thoracic Oncology, 2023 - jto.org
Methods This retrospective study was conducted across nine hospitals in Vietnam.
Advanced EGFR-mutant NSCLC patients who received afatinib as first-line therapy between …
Advanced EGFR-mutant NSCLC patients who received afatinib as first-line therapy between …
[HTML][HTML] Real-world analysis of first-line afatinib in patients with EGFR-mutant non-small cell lung cancer and brain metastasis: survival and prognostic factors
J Kim, TW Jang, CM Choi, MH Kim, SY Lee… - Translational Lung …, 2023 - ncbi.nlm.nih.gov
Background Overall survival (OS) in patients with non-small cell lung cancer (NSCLC) and
brain metastases (BMs) is poor. We aimed to identify prognostic factors and ascertain …
brain metastases (BMs) is poor. We aimed to identify prognostic factors and ascertain …